TEDOVA: vaccine OSE2101+/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer

被引：0

作者：

Kabirian, Rayan ^{[1
,2
]}

Tredan, Olivier ^{[2
,3
]}

Marme, Frederik ^{[4
,5
]}

Paoletti, Xavier ^{[6
]}

Eberst, Lauriane ^{[2
,7
]}

Lebreton, Coriolan ^{[2
,8
]}

Rouge, Thibault De La Motte ^{[2
,9
]}

Sabatier, Renaud ^{[2
,10
]}

Angelergues, Antoine ^{[2
,11
]}

Fabbro, Michel ^{[2
,12
]}

Van Gorp, Toon ^{[13
]}

Mansi, Laura ^{[2
,14
]}

Gladieff, Laurence ^{[2
,15
]}

Kaczmarek, Emilie ^{[2
,16
]}

Alexandre, Jerome ^{[2
,17
]}

Grellety, Thomas ^{[2
,18
]}

Favier, Laure ^{[2
,19
]}

Welz, Julia ^{[5
,20
]}

Frenel, Jean-Sebastien ^{[2
,21
]}

Leary, Alexandra ^{[1
,2
]}

机构：

[1] Gustave Roussy, Dept Med Oncol, Villejuif, France

[2] GINECO, Paris, France

[3] Ctr Leon Berard, Lyon, France

[4] Heidelberg Univ, Med Fac Mannheim, Mannheim, Germany

[5] AGO Study Grp, Mannheim, Germany

[6] Inst Curie, Biostat Unit, Paris, France

[7] ICANS, Inst Cancerol Strasbourg Europe, Strasbourg, France

[8] Inst Bergonie, Bordeaux, France

[9] Ctr Eugene Marquis, Rennes, France

[10] Aix Marseille Univ, Inst Paoli Calmettes, CRCM, Dept Med Oncol,Inserm, Marseille, France

[11] Grp Hosp Diaconesses Croix St Simon, Paris, France

[12] Inst Canc Montpellier ICM, Montpellier, France

[13] Univ Hosp Leuven, Leuven Canc Inst, Div Gynaecol Oncol, BGOG, Leuven, Belgium

[14] CHU Besancon, Hop Jean Minjoz, Besancon, France

[15] IUCT Oncopole, Oncopole Claudius Regaud, Toulouse, France

[16] Ctr Oscar Lambret, Lille, France

[17] Univ Paris Cite, Hop Cochin, AP HP, Paris, France

[18] Ctr Hosp Cote Basque, Bayonne, France

[19] Ctr Georges Francois Leclerc, Dijon, France

[20] Evang Kliniken Essen Mitte ESSEN, Essen, Germany

[21] Ctr Rene Gauducheau, Inst Cancerol Ouest, F-44800 St Herblain, France

来源：

FUTURE ONCOLOGY | 2024年 / 20卷 / 35期

关键词：

anti PD1; maintenance; OSE2101; pembrolizumab; platinum-sensitive; recurrent ovarian cancer; vaccine; ANTITUMOR-ACTIVITY; BEVACIZUMAB; OLAPARIB; EFFICACY; TRIAL; BLOCKADE; SAFETY;

D O I：

10.1080/14796694.2024.2386922

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.

引用

页码：2699 / 2708

页数：10

共 50 条

[1] TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum
Leary, Alexandra
Gladieff, Laurence
Sabatier, Renaud
Paoletti, Xavier
Marme, Frederik
Van Gorp, Toon
Alexandre, Jerome
Grellety, Thomas
Angelergues, Antoine
Simmet, Victor
Grenier, Julien
Augereau, Paule
Fabbro, Michel
Combe, Pierre
Hardy-Bessard, Anne-Claire
Kaczmarek, Emilie
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab versus best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.
Leary, Alexandra
Deluche, Elise
Favier, Laure
Paoletti, Xavier
Mansi, Laura
Tredan, Olivier
Eberst, Lauriane
Rouge, Thibault De la Motte
Joly, Florence
Lortholary, Alain
You, Benoit
Marme, Frederik
Van Gorp, Toon
Floquet, Anne
Frenel, Jean-Sebastien
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
Guerra Alia, Eva Maria
Sempere Ortega, Cayetano
Cortes Salgado, Alfonso
Sanchez Martinez, Concepcion
Galindo Alvarez, Julio
Perez Miez, Belen
CASE REPORTS IN ONCOLOGY, 2019, 12 (02): : 447 - 455
[4] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R.
Monk, B. J.
Herrstedt, J.
Oza, A. M.
Mahner, S.
Redondo, A.
Fabbro, M.
Ledermann, J. A.
Lorusso, D.
Vergote, I.
Ben-Baruch, N. E.
Marth, C.
Madry, R.
Christensen, R. D.
Berek, J. S.
Dorum, A.
Tinker, A. V.
du Bois, A.
Gonzalez-Martin, A.
Follana, P.
Benigno, B.
Rosenberg, P.
Gilbert, L.
Rimel, B. J.
Buscema, J.
Balser, J. P.
Agarwal, S.
Matulonis, U. A.
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2154 - 2164
[5] Utilization of maintenance therapy for platinum-sensitive recurrent ovarian cancer
Wall, J. A.
Davis, A. M.
Beer, H.
Foxall, M.
Londono, A. I.
McGwin, G.
Leath, C. A., III
Arend, R. C.
GYNECOLOGIC ONCOLOGY, 2020, 159 : 115 - 115
[6] Concerns with "maintenance chemotherapy" for patients with recurrent platinum-sensitive ovarian cancer
Markman, M
GYNECOLOGIC ONCOLOGY, 1999, 73 (03) : 469 - 470
[7] Maintenance chemotherapy among patients with platinum-sensitive recurrent ovarian cancer
Yang Qiuan
Zhao Weiping
Wang QingweiThe Cancer Center of the Affiliated Hospital of Shandong Medical University
现代妇产科进展, 1999, (04) : 394 - 395
[8] Management of platinum-sensitive recurrent ovarian cancer
Pfisterer, Jacobus
Ledermann, Jonathan A.
SEMINARS IN ONCOLOGY, 2006, 33 (02) : S12 - S16
[9] Concerns with "maintenance chemotherapy" for patients with recurrent platinum-sensitive ovarian cancer - Reply
Eltabbakh, GH
Piver, MS
GYNECOLOGIC ONCOLOGY, 1999, 73 (03) : 470 - 472
[10] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer EDITORIAL COMMENT
不详
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2017, 72 (02) : 91 - 92

← 1 2 3 4 5 →